Export 41 results:
Author Title [ Type(Desc)] Year
Filters: Author is VanVeldhuisen, Paul C  [Clear All Filters]
Journal Article
F. Ederer, Gaasterland, D. A., Dally, L. G., Kim, J., VanVeldhuisen, P. C., Blackwell, B., Prum, B., Shafranov, G., Allen, R. C., and Beck, A., The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results., Ophthalmology, vol. 111, no. 4, pp. 651-64, 2004.
J. Kim, Dally, L. G., Ederer, F., Gaasterland, D. E., VanVeldhuisen, P. C., Blackwell, B., E Sullivan, K., Prum, B., Shafranov, G., Beck, A., and Spaeth, G. L., The Advanced Glaucoma Intervention Study (AGIS): 14. Distinguishing progression of glaucoma from visual field fluctuations., Ophthalmology, vol. 111, no. 11, pp. 2109-16, 2004.
R. N. Khurana, Oden, N. L., VanVeldhuisen, P. C., Scott, I. U., Blodi, B. A., and Ip, M. S., Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trial., Graefes Arch Clin Exp Ophthalmol, vol. 239, no. 7, pp. 1839-1851, 2021.
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., and Blodi, B. A., Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion (SCORE2) Report 18, JAMA Ophthalmol, vol. 140, no. 5, pp. 458-464, 2022.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., King, J., Antoszyk, A. N., Peters, M. A., and Tolentino, M., Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4., JAMA Ophthalmol, vol. 135, no. 6, pp. 639-649, 2017.
I. U. Scott, VanVeldhuisen, P. C., Oden, N. L., Ip, M. S., Blodi, B. A., Hartnett, M. Elizabeth, and Cohen, G., Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10., Ophthalmology, vol. 118, no. 2, pp. 345-52, 2011.
H. J. Landy, S Laughon, K., Bailit, J. L., Kominiarek, M. A., Gonzalez-Quintero, V. Hugo, Ramirez, M., Haberman, S., Hibbard, J., Wilkins, I., D Branch, W., Burkman, R. T., Gregory, K., Hoffman, M. K., Learman, L. A., Hatjis, C., VanVeldhuisen, P. C., Reddy, U. M., Troendle, J., Sun, L., and Zhang, J., Characteristics associated with severe perineal and cervical lacerations during vaginal delivery., Obstet Gynecol, vol. 117, no. 3, pp. 627-35, 2011.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Altaweel, M., and Berinstein, D. M., Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial., JAMA Ophthalmol, vol. 136, no. 4, pp. 337-345, 2018.
B. W. Gillespie, Niziol, L. M., Ehrlich, J. R., Johnson, C. A., Caprioli, J., VanVeldhuisen, P. C., Lichter, P. R., and Musch, D. C., Demographic, Comorbid, and Clinical Variables Associated With Pointwise Visual Field Damage in Glaucoma: Data From the AGIS and CIGTS Clinical Trials., Transl Vis Sci Technol, vol. 10, no. 12, p. 28, 2021.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Awh, C. C., Kunimoto, D. Y., Marcus, D. M., Wroblewski, J. J., and King, J., Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial., JAMA, vol. 317, no. 20, pp. 2072-2087, 2017.
D. G. Birch, Bernstein, P. S., Iannacone, A., Pennesi, M. E., Lam, B. L., Heckenlively, J., Csaky, K., Hartnett, M. Elizabeth, Winthrop, K. L., Jayasundera, T., Hughbanks-Wheaton, D. K., Warner, J., Yang, P., Fish, G. Edd, Teske, M. P., Sklaver, N. L., Erker, L., Chegarnov, E., Smith, T., Wahle, A., VanVeldhuisen, P. C., McCormack, J., Lindblad, R., Bramer, S., Rose, S., Zilliox, P., Francis, P. J., and Weleber, R. G., Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial., JAMA Ophthalmol, vol. 136, no. 8, pp. 849-856, 2018.
G. Sharma, Oden, N., VanVeldhuisen, P. C., and Bogenschutz, M. P., Hair analysis and its concordance with self-report for drug users presenting in emergency department., Drug Alcohol Depend, vol. 167, pp. 149-55, 2016.
A. A. Aref, Scott, I. U., Oden, N. L., Ip, M. S., Blodi, B. A., and VanVeldhuisen, P. C., Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion: SCORE Study Report 15., JAMA Ophthalmol, vol. 133, no. 9, pp. 1022-9, 2015.
A. A. Aref, Scott, I. U., VanVeldhuisen, P. C., King, J., Ip, M. S., Blodi, B. A., and Oden, N. L., Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial., JAMA Ophthalmol, vol. 139, no. 12, pp. 1285-1291, 2021.
J. S. Peterson, Rockwell, K., Scott, I. U., Ip, M. S., VanVeldhuisen, P. C., and Blodi, B. A., LONG-TERM PHYSICAL STABILITY, STERILITY, AND ANTI-VEGF BIOACTIVITY OF REPACKAGED BEVACIZUMAB IN 2-ML GLASS VIALS., Retina, vol. 39, no. 9, pp. 1802-1809, 2019.
M. S. Ip, Oden, N. L., Scott, I. U., VanVeldhuisen, P. C., Blodi, B. A., Ghuman, T., and Baker, C. W., Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study., JAMA Ophthalmol, vol. 137, no. 3, pp. 281-287, 2019.
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., and Chan, C. K., Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial., JAMA Ophthalmol, 2019.
I. U. Scott, VanVeldhuisen, P. C., Oden, N. L., Ip, M. S., and Blodi, B. A., Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion, Am J Ophthalmol, vol. 240, pp. 330-341, 2022.
E. Margaret Maloney, Yamano, Y., VanVeldhuisen, P. C., Sawada, T., Kim, N., Cranston, B., Hanchard, B., Jacobson, S., and Hisada, M., Natural history of viral markers in children infected with human T lymphotropic virus type I in Jamaica., J Infect Dis, vol. 194, no. 5, pp. 552-60, 2006.
I. U. Scott, VanVeldhuisen, P. C., Barton, F., Oden, N. L., Ip, M. S., Blodi, B. A., Worrall, M., and Fish, G. E., Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical Trial., JAMA Ophthalmol, 2019.
N. L. Oden, VanVeldhuisen, P. C., Wakim, P. G., Trivedi, M. H., Somoza, E., and Lewis, D., Power of automated algorithms for combining time-line follow-back and urine drug screening test results in stimulant-abuse clinical trials., Am J Drug Alcohol Abuse, vol. 37, no. 5, pp. 350-7, 2011.
T. G Ray, Bahorik, A. L., VanVeldhuisen, P. C., Weisner, C. M., Rubinstein, A. L., and Campbell, C. I., Prescription opioid registry protocol in an integrated health system., Am J Manag Care, vol. 23, no. 5, pp. e146-e155, 2017.